Á lódáil...
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
Although most autoimmune diseases are considered to be CD4 T cell‐ or antibody‐mediated, many respond to CD20‐depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off‐label in...
Na minha lista:
| Foilsithe in: | Clin Exp Immunol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
John Wiley and Sons Inc.
2020
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7405500/ https://ncbi.nlm.nih.gov/pubmed/32671831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13495 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|